-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Pyxis Oncology, Maintains $8 Price Target

Benzinga·03/19/2025 14:44:15
Listen to the news
RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and maintains $8 price target.